Projeto & Beleza Estética: Quando Ciência e Estética se Encontram para Transformar Vidas
Com mais de 20 anos de experiência, Uilma Glicia lidera a clínica que alia tecnologia, protocolos personalizados e atendimento humanizado, tornando-se referência em saúde estética em São Paulo. Fundada em 10 de abril de 2018, a Projeto & Beleza Estética surgiu com a missão de devolver a beleza natural de cada paciente, unindo ciência e estética. Sob a liderança de Uilma Glicia, esteticista com mais de duas décadas de experiência, a clínica se tornou referência em tratamentos faciais e corporais personalizados, priorizando a saúde, o bem-estar e a autoestima de homens e mulheres. Protocolos Personalizados e Atendimento Humanizado O diferencial da Projeto & Beleza Estética está nos protocolos personalizados. Cada paciente passa por uma avaliação detalhada, que identifica suas necessidades específicas, seja no cuidado facial ou corporal. A partir daí, são aplicados tratamentos que combinam tecnologias avançadas e terapias manuais, garantindo resultados eficazes com total segurança. “Nosso trabalho é cuidar do paciente de dentro para fora, garantindo que cada tratamento seja único e transformador”, afirma Uilma Glicia. A clínica oferece serviços como: Superando Desafios e Buscando Reconhecimento Nos primeiros anos, a Projeto & Beleza Estética contou com parcerias com empresas como Groupon e Peixe Urbano. Apesar das expectativas não terem sido atendidas — resultando em um débito de R$ 350.000,00 em serviços prestados —, a clínica manteve sua resiliência e comprometimento. “Cada desafio é uma oportunidade de crescimento. Continuamos acreditando no nosso trabalho, na qualidade dos nossos serviços e no potencial de reconhecimento do nosso esforço”, afirma Uilma. Uilma Glicia: Experiência, Inovação e Método Próprio Com mais de 20 anos atuando na saúde estética, Uilma Glicia é especialista em estética facial, corporal e avançada, formada na Escola Esthetics – Life, em Santo André (SP). Ela é criadora do método Shape Saudável, que combina terapias manuais e tecnologias modernas para entregar resultados exclusivos e personalizados. Seu objetivo é garantir que cada paciente não apenas melhore a aparência, mas também recupere a autoestima e o bem-estar, promovendo uma abordagem integral da saúde estética. Visão de Futuro e Compromisso com a Saúde A Projeto & Beleza Estética visa expandir o conceito de cuidado estético humanizado, tornando o autocuidado uma prioridade na vida de seus pacientes. Para Uilma, a estética vai além da beleza superficial: é uma forma de cuidar da saúde física e emocional. “Nossa missão é entregar tratamentos que realmente transformem a vida das pessoas. Queremos que cada paciente se sinta valorizado, cuidado e confiante”, conclui a CEO. Projeto & Beleza Estética – Nossa análise
Metabolic Weight Loss: New Protocol Targets Cancer
An innovative approach with Tirzepatide by Dr. Daniel Dias Machado is redefining chronic disease prevention and optimizing overall health. A new frontier in preventive medicine is reshaping the concept of weight loss and expanding the horizons of longevity. This is the Metabolic Weight Loss Protocol with Tirzepatide, created by Dr. Daniel Dias Machado, a biomedical scientist with advanced training in Integrative Medicine from the renowned Faculty of Zurich, Switzerland. Far beyond aesthetics, the method transforms metabolism into an active barrier against chronic diseases, including cancer, and has already captured the attention of physicians and scientists worldwide. SCIENTIFICALLY BASED WEIGHT LOSS AND DISEASE PREVENTION In a context where diets frequently fail and invasive methods multiply, Dr. Daniel’s protocol stands out for achieving real and sustainable results. Its triple goal is rapid weight reduction, control of silent inflammation, and cancer prevention — all in a single therapeutic plan. The core of the strategy is Tirzepatide, a next-generation molecule known for its dual action: glycemic control and accelerated fat reduction. In Dr. Machado’s protocol, Tirzepatide plays an innovative role: reprogramming metabolism to prevent the onset of serious diseases. “It’s not just about losing weight; it’s about neutralizing the biological environment in which diseases settle,” he explains. METABOLIC TRANSFORMATION AND THE CONCEPT OF ONCOTAXIS According to Dr. Daniel, the real enemy is not only excess fat but the inflammatory environment it creates — fertile ground for tumor cell proliferation. The protocol tackles the root cause by fighting silent chronic inflammation, which alters tissue pH, weakens the immune system, and favors the emergence of complex diseases. Key actions include: A central concept is oncotaxis, little known outside academia. It describes the selective migration of cancer cells to inflamed and low-oxygen regions. By reorganizing the “biological terrain,” the protocol makes the body hostile to cancer and fertile for health. NATIONAL SCIENTIFIC RECOGNITION: THE ANNA NERY HEALTH AWARD Dr. Daniel’s research in biological and metabolic medicine, initiated in 2022, two years after the first global studies with Tirzepatide, earned him one of the highest distinctions in Brazilian health: the Anna Nery Health Award, granted by the Legislative Assembly of the State of Rio de Janeiro. This award originates from Decree-Law No. 8,489 of December 27, 1945, signed by President Getúlio Vargas, which established official honors to Anna Nery — the pioneer of nursing in Brazil and a symbol of humanitarian dedication. Receiving this award means that the honoree’s work is recognized as being of relevant public interest and national impact. For the scientific community and Brazil’s public health system, the award serves as a seal of excellence, ethical commitment, and lasting social contribution. ALIGNMENT WITH GLOBAL MEDICAL SCIENCE The foundations of this protocol resonate with the work of Nobel laureates Harald zur Hausen (2008) and James P. Allison (2018), who highlighted the importance of preventing cancer-friendly environments and strengthening immunity. They also align with Elizabeth Blackburn (2009), who demonstrated the role of metabolic interventions in extending healthy lifespan, and David Sinclair (Harvard University), a leading advocate for metabolic optimization as a pillar of disease prevention. This international convergence confirms that the innovation born in Latin American clinical practice is fully aligned with the cutting edge of precision medicine. PROVEN LARGE-SCALE RESULTS More than 1,000 patients have already been treated in Dr. Daniel’s clinics in Porto Alegre, São Paulo, and Lima (Peru). With rigorous monitoring — including segmental bioimpedance and high-precision laboratory tests — the results are remarkable: With the potential to eliminate up to 12 kg of visceral fat in 90 days, the impact goes far beyond aesthetics: it rebuilds metabolic architecture, strengthening immunity and vitality. AN INTEGRATED AND SUSTAINABLE METHOD The protocol combines internationally traceable compounded formulations, structured consultations following European functional medicine standards, a multidisciplinary team trained abroad, and continuous metabolic education, ensuring not only effective weight loss but also long-term prevention of chronic diseases. A NEW MILESTONE FOR BIOMEDICINE: JUDICIAL EXPERT APPOINTMENT In 2025, Dr. Daniel Dias Machado was appointed as a Judicial Expert in the capacity of Biomedical Scientist by the Court of Justice of the State of São Paulo, with registration and recognition from the Regional Council of Biomedicine of the 1st Region (CRBM-1). This appointment is a historic milestone for Biomedicine, as it expands the profession’s scope in forensic and legal medicine and reinforces the credibility of biomedical science as a decisive technical authority in judicial cases. It demonstrates that biomedical expertise is officially recognized as critical in health-related legal matters, clinical evaluations, and technical evidence analysis. THE JOURNEY AND VISION OF DR. DANIEL DIAS MACHADO Dr. Daniel Dias Machado holds a degree in Biomedicine from Centro Universitário UniBTA, located on Avenida Paulista—one of South America’s largest and most prestigious medical education hubs. He also served as a researcher in Clinical Pathology at Centro Universitário ETEP in São José dos Campos, a region recognized as the “Brazilian Silicon Valley” and home to Embraer and major technology companies. In addition to graduating with honors in Biomedicine, Dr. Machado earned a degree in Dental Sciences with a specialization in Orofacial Medicine and Oral & Orofacial Aesthetic, Reconstructive, and Reparative Surgery from the Faculty of Dentistry of Manaus, the leading center for orofacial medical research in northern Brazil, which collaborates on studies across Brazil and neighboring countries. He further completed postgraduate studies in Integrative Medicine at the Faculty of Zurich, Switzerland, and earned a Master’s degree in Head and Neck Surgery from the Technological University of Santa Cruz de Tenerife, Spain. Currently, he is a Master’s-level researcher in Temporomandibular Joint Dysfunction and Orofacial Pain at the renowned Faculdade São Leopoldo Mandic on Avenida Paulista in São Paulo. In parallel, he serves as a university professor at Faculdade CTA, Brazil’s largest academic center dedicated to the anatomy of aesthetic medicine. Conclusion: Science, Prevention, and Public Recognition In the era of personalized medicine, rapid weight loss alone is not enough. It is crucial to understand and neutralize the inflammatory processes that lead to chronic disease. Dr. Daniel Dias Machado’s Metabolic Weight Loss Protocol is more
This AI Founder Became A Billionaire By Building ChatGPT For Doctors
For doctors trying to stay abreast of the latest medical breakthroughs, reviewing the latest research is like being shot in the face with a water cannon. A new paper is published every 30 seconds. Trying to comb through it all to come up with a diagnosis or treatment plan that reflects the best current options while seeing 20 patients a day is a near-impossible task. “We talk about the golden age of biotechnology where there are new drugs and better drugs developed all the time. But it is like the dark ages for physicians because of burnout,” Daniel Nadler, cofounder and CEO of OpenEvidence, told Forbes. “There is this enormous firehose of information they need to stay on top of, and the human brain is limited in its capacity to read millions of studies.” So Nadler, 42, a Harvard Ph.D. who sold his previous company for $550 million back in 2018, set out to solve the problem with artificial intelligence. Now, the startup’s proprietary algorithms search millions of peer-reviewed publications, including in top journals like the New England Journal of Medicine and the Journal of the American Medical Association, to help doctors find the best answers fast, with full citations to papers so doctors can read more for themselves. The software is free for verified doctors to use and makes money through advertising–much like Google does. “I think OpenEvidence looks like it’s going to be for healthcare what Google was for the Internet,” said Kleiner Perkins billionaire chairman John Doerr, who invested in the company personally as well as through his firm, adding, “It’s the free-for-physician model that’s the magic here.” Since its founding in 2022, Miami-based OpenEvidence has signed up 40% of doctors in the United States, or more than 430,000, and is adding new ones at a current rate of 65,000 per month. Its revenue from advertising is now coming in at an annualized rate estimated at $50 million. That’s not huge, but thanks to the software’s rapid adoption, investors are betting big: OpenEvidence has raised $210 million led by GV (Google’s venture arm) and Kleiner Perkins at a valuation of $3.5 billion, up from $1 billion at its last financing in February, Nadler told Forbes. Other storied VC firms like Coatue, Conviction and Thrive Capital also invested. The new investment makes Nadler, who owns roughly 60% of the company, a billionaire, with a net worth that Forbes estimates at $2.3 billion. Cofounder Zack Ziegler, the company’s 30-year-old chief technology officer, owns some 10% of the business, worth about $350 million. Nadler was able to hold on to such a large stake by being its first seed investor, putting in some $10 million of his own money before raising any VC funding. “One of the great things about being a second-time entrepreneur is, I’m not an idiot,” Nadler said. “I think the second thing is going to be bigger than the first so maybe the first $10 million should come from me. That’s by far the smartest financial decision I made in my life…..I wanted to bet on myself.” The problem OpenEvidence is addressing is enormous, and one that’s only getting bigger. Medical literature is proliferating at a meteoric rate—doubling in size every five years—as new treatment options like gene therapies are developed and scientists learn more about how different diseases and drugs may interact with each other. Sorting through all of it is a herculean task: some papers are excellent, some are bad and many more are outdated. (With AI being used to publish and review research papers, the problem has only gotten worse.) Meanwhile, physicians in the United States are increasingly strapped for time, given a growing shortage of medical professionals—creating an opportunity for startups to build technology that can help provide better care and relieve pressure on doctors. “When everyone was scrambling to come out of crypto, I was like, ‘I am just going to run circles around all of you.’”Daniel Nadler, cofounder and CEO, OpenEvidence OpenEvidence isn’t the first company to try to make sense of the overload of medical publications; Wolters Kluwer’s UpToDate has been around for decades and has recently been incorporating AI, along with advice from experts, to do the same thing. But it is the first to build software that integrates AI from the start to make it easier for doctors to find answers to pressing clinical questions and to do so far more accurately than ChatGPT. Doctors now use OpenEvidence on some 8.5 million consultations a month. Because the tool isn’t considered diagnostic, it doesn’t need FDA approval as algorithms used to detect strokes or sepsis in patients do. And since doctors can download it or use it online for free, it can bypass the lengthy and bureaucratic procurement process with hospitals or large group practices. That’s helped the company sign up doctors at an ever-faster clip. Dr. Susan Wolver, an internist in Richmond, Va., has become a true believer, using OpenEvidence to write prior authorization letters and look up details of drugs. Most dramatically, while she was on a domestic flight recently, an immunocompromised passenger nearly fainted in the bathroom. Wolver turned to OpenEvidence to figure out the patient’s immune-system risks and come up with a treatment plan on the spot. “I don’t think a day goes by when I don’t use it,” she said. Nadler grew up in Toronto where his parents were part of the great wave of post-war Eastern European immigrants–his father from Romania and his mother from Poland. “My grandfather was in Auschwitz and survived,” he said. “After the second world war, my grandfather wanted to come to America, and America wasn’t letting people in so they made their way to Canada.” As a kid, Nadler was competitive to a fault, dabbling in memory games to see whether he could recite more pages of a Hamlet soliloquy than a friend. “I was a total nerd,” he said. A Mensa member, he found school boring, and after getting a bachelor’s degree at the University of Toronto, applied to Harvard for grad school, hoping for a greater challenge. Once there, he got a Ph.D
Meta e Executivos Fecham Acordo em Processo Bilionário sobre Privacidade no Facebook
Decisão foi tomada no segundo dia do julgamento em Delaware; detalhes do acordo permanecem confidenciais Um processo movido por acionistas contra Mark Zuckerberg e outros nomes de alto escalão da Meta foi encerrado nesta quinta-feira (17) após um acordo entre as partes. A ação, que tramitava na Corte de Chancelaria de Delaware, buscava responsabilizar pessoalmente Zuckerberg, o investidor Marc Andreessen e ex-executivos da companhia, como Sheryl Sandberg, por perdas estimadas em US$ 8 bilhões devido a violações recorrentes da privacidade de usuários do Facebook. O julgamento, que havia começado recentemente, foi interrompido pela juíza Kathaleen McCormick, que reconheceu o encerramento amigável do caso e parabenizou ambas as partes. Os advogados de defesa não chegaram a se manifestar publicamente, e os termos do acordo não foram divulgados. Segundo o advogado Sam Closic, que representa os acionistas, o entendimento foi alcançado de maneira ágil. Um dos réus mais aguardados para depor nesta etapa era Marc Andreessen, membro do conselho da Meta. Os acionistas alegavam que os réus deveriam arcar com os custos de multas e despesas legais enfrentadas pela empresa — entre elas, a multa de US$ 5 bilhões aplicada pelo governo americano em 2019, por descumprimento de um acordo anterior com a Comissão Federal de Comércio (FTC), firmado em 2012. Os acusados sempre rejeitaram as acusações, classificando-as como exageradas. A Meta, que mudou de nome em 2021 e não era ré diretamente no processo, preferiu não se pronunciar sobre o desfecho. Os advogados dos réus também não comentaram até o momento.
